Name: UMIN ID:
Unique ID issued by UMIN | UMIN000025473 |
---|---|
Receipt number | R000028899 |
Scientific Title | Phase II study of VI (vincristine, irinotecan) / VPC (vincristine, pirarubicin, cyclophosphamide) / IE (ifosfamide, etoposide) / VAC (vincristine, actinomycin D, cyclophosphamide) for patients with newly diagnosed high-risk rhabdomyosarcoma. |
Date of disclosure of the study information | 2017/02/01 |
Last modified on | 2023/07/05 15:36:14 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2016/12/29 12:48:32 | ||
2 | Update | 2019/07/12 18:17:35 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel |
|
3 | Update | 2019/07/12 18:20:19 | Last follow-up date |
|
4 | Update | 2021/07/03 11:01:12 | Last follow-up date |
|
5 | Update | 2023/07/05 15:36:14 | Recruitment status Date of IRB |